CR20120576A - Inhibidores de pirazolil quinazolina cinasa - Google Patents

Inhibidores de pirazolil quinazolina cinasa

Info

Publication number: CR20120576A
Authority: CR; Costa Rica
Prior art keywords: pirazolil; quinazolina; cinasa; inhibitors; cinasa inhibitors
Prior art date: 2010-04-30

Application number

CR20120576A

Other languages

English (en)

Inventor

Gordon Saxty

Christopher William Murray

Valerio Berdini

Gilbert Ebai Besong

Christopher Charles Frederick Hamlett

Christopher Norbert Johnson

Steven John Woodhead

Michael Reader

David Charles Rees

Laurence Anne Mevellec

Patrick Rene Angibaud

Eddy Jean Edgard Freyne

Tom Cornelis Hortense Govaerts

Johan Erwin Edmond Weerts

Timothy Pietro Suren Perera

Ronaldus Arnodus Hendrika Joseph Gilissen

Berthold Wroblowski

Jean Fernand Armand Lacrampe

Alexandra Papanikos

Oliver Alexis Georges Querolle

Elisabeth Therese Jeanne Pasquier

Isabelle Noelle Constance Pilatte

Pascal Ghislain Andre Bonnet

Werner Constant Johan Embrechts

Rhalid Akkari

Lieven Meerpoel

Original Assignee

Astex Therapeutics Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-04-30

Filing date

2012-11-13

Publication date

2013-03-04

2012-11-13 Application filed by Astex Therapeutics Ltd filed Critical Astex Therapeutics Ltd

2013-03-04 Publication of CR20120576A publication Critical patent/CR20120576A/es

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6524—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having four or more nitrogen atoms as the only ring hetero atoms

CR20120576A 2010-04-30 2012-11-13 Inhibidores de pirazolil quinazolina cinasa CR20120576A (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US32988410P	2010-04-30	2010-04-30
GB201007286A GB201007286D0 (en)	2010-04-30	2010-04-30	New compounds

Publications (1)

Publication Number	Publication Date
CR20120576A true CR20120576A (es)	2013-03-04

Family

ID=42289929

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
CR20180339A CR20180339A (es)	2010-04-30	2011-04-28	INHIBIDORES DE PIRAZOLIL QUINAZOLINA CINASA (Divisional 2012-0576)
CR20120576A CR20120576A (es)	2010-04-30	2012-11-13	Inhibidores de pirazolil quinazolina cinasa

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
CR20180339A CR20180339A (es)	2010-04-30	2011-04-28	INHIBIDORES DE PIRAZOLIL QUINAZOLINA CINASA (Divisional 2012-0576)

Country Status (35)

Country	Link
US (6)	US8895601B2 (es)
EP (3)	EP3178818B1 (es)
JP (1)	JP5639261B2 (es)
KR (2)	KR101889565B1 (es)
CN (2)	CN102858765B (es)
AP (1)	AP3210A (es)
AR (1)	AR080982A1 (es)
AU (2)	AU2011247047B2 (es)
BR (1)	BR112012027509B1 (es)
CA (1)	CA2796204C (es)
CL (1)	CL2012003048A1 (es)
CR (2)	CR20180339A (es)
CY (2)	CY1121882T1 (es)
DK (3)	DK2563775T3 (es)
EA (2)	EA028599B1 (es)
EC (1)	ECSP12012318A (es)
ES (3)	ES2899937T3 (es)
GB (1)	GB201007286D0 (es)
HR (1)	HRP20211675T1 (es)
HU (3)	HUE033702T2 (es)
IL (1)	IL222600A (es)
IN (1)	IN2012MN02591A (es)
JO (1)	JO3366B1 (es)
LT (3)	LT3178818T (es)
ME (1)	ME01825B (es)
MX (2)	MX365702B (es)
MY (2)	MY191669A (es)
NZ (1)	NZ602726A (es)
PL (3)	PL2563775T3 (es)
PT (3)	PT3590934T (es)
RS (3)	RS55863B1 (es)
SG (2)	SG10201708578QA (es)
SI (3)	SI2563775T1 (es)
TW (1)	TWI545122B (es)
WO (1)	WO2011135376A1 (es)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8053440B2 (en)	2007-02-01	2011-11-08	Resverlogix Corporation	Compounds for the prevention and treatment of cardiovascular diseases
NZ617779A (en)	2009-03-18	2015-08-28	Resverlogix Corp	Novel anti-inflammatory agents
KR20180096823A (ko)	2009-04-22	2018-08-29	리스버로직스 코퍼레이션	신규한 소염제
GB201007286D0 (en)	2010-04-30	2010-06-16	Astex Therapeutics Ltd	New compounds
GB201020179D0 (en)	2010-11-29	2011-01-12	Astex Therapeutics Ltd	New compounds
US8754114B2 (en)	2010-12-22	2014-06-17	Incyte Corporation	Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
GB201118656D0 (en)	2011-10-28	2011-12-07	Astex Therapeutics Ltd	New compounds
GB201118652D0 (en)	2011-10-28	2011-12-07	Astex Therapeutics Ltd	New compounds
GB201118675D0 (en)	2011-10-28	2011-12-14	Astex Therapeutics Ltd	New compounds
GB201118654D0 (en)	2011-10-28	2011-12-07	Astex Therapeutics Ltd	New compounds
GB201209609D0 (en) *	2012-05-30	2012-07-11	Astex Therapeutics Ltd	New compounds
GB201209613D0 (en)	2012-05-30	2012-07-11	Astex Therapeutics Ltd	New compounds
EP3822273B1 (en)	2012-06-13	2024-04-10	Incyte Holdings Corporation	Substituted tricyclic compounds as fgfr inhibitors
RS62233B1 (sr)	2012-07-11	2021-09-30	Blueprint Medicines Corp	Inhibitori receptora fibroblast faktora rasta
WO2014026125A1 (en)	2012-08-10	2014-02-13	Incyte Corporation	Pyrazine derivatives as fgfr inhibitors
MX338885B (es) *	2012-10-15	2016-05-04	Resverlogix Corp	Compuestos utiles en la sintesis de compuestos de benzamida.
AU2013337277B2 (en)	2012-11-05	2018-03-08	Foundation Medicine, Inc.	Novel NTRK1 fusion molecules and uses thereof
US9719970B2 (en)	2012-11-30	2017-08-01	Waters Technologies Corporation	Methods and apparatus for the analysis of vitamin D metabolites
US9266892B2 (en)	2012-12-19	2016-02-23	Incyte Holdings Corporation	Fused pyrazoles as FGFR inhibitors
AR094812A1 (es)	2013-02-20	2015-08-26	Eisai R&D Man Co Ltd	Derivado de piridina monocíclico como inhibidor del fgfr
TWI647220B (zh)	2013-03-15	2019-01-11	美商西建卡爾有限責任公司	雜芳基化合物及其用途
CN105307657B (zh) *	2013-03-15	2020-07-10	西建卡尔有限责任公司	杂芳基化合物和其用途
UA120248C2 (uk)	2013-03-15	2019-11-11	Селджен Кар Ллс	Гетероарильні сполуки та їх застосування
SG10201708520YA (en)	2013-04-19	2017-12-28	Incyte Corp	Bicyclic heterocycles as fgfr inhibitors
GB201307577D0 (en) *	2013-04-26	2013-06-12	Astex Therapeutics Ltd	New compounds
CN104163794A (zh) *	2013-10-17	2014-11-26	中国药科大学	2-氨基芳环类血管内皮生长因子受体(vegfr)抑制剂及其制备方法和用途
CN110028491B (zh)	2013-10-25	2022-02-11	缆图药品公司	纤维母细胞生长因子受体抑制剂
WO2015108992A1 (en)	2014-01-15	2015-07-23	Blueprint Medicines Corporation	Heterobicyclic compounds and their use as fgfr4 receptor inhibitors
HUE053653T2 (hu)	2014-03-26	2021-07-28	Astex Therapeutics Ltd	FGFR inhibitor és IGF1R inhibitor kombinációi
JO3512B1 (ar)	2014-03-26	2020-07-05	Astex Therapeutics Ltd	مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
ES2856482T3 (es)	2014-03-26	2021-09-27	Astex Therapeutics Ltd	Combinaciones de inhibidores de FGFR y cMet para el tratamiento del cáncer
CN105017227B (zh) *	2014-07-08	2018-03-09	四川百利药业有限责任公司	N‑(1h‑吡唑‑5‑基)喹唑啉‑4‑胺类化合物
KR102344105B1 (ko)	2014-08-18	2021-12-29	에자이 알앤드디 매니지먼트 가부시키가이샤	모노시클릭 피리딘 유도체의 염 및 이의 결정
US20160090633A1 (en) *	2014-09-26	2016-03-31	Janssen Pharmaceutica Nv	Use of fgfr mutant gene panels in identifying cancer patients that will be responsive to treatment with an fgfr inhibitor
US10851105B2 (en)	2014-10-22	2020-12-01	Incyte Corporation	Bicyclic heterocycles as FGFR4 inhibitors
TWI695837B (zh)	2014-12-04	2020-06-11	比利時商健生藥品公司	作為激酶調節劑之***並嗒
JOP20200201A1 (ar) *	2015-02-10	2017-06-16	Astex Therapeutics Ltd	تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين
WO2016134294A1 (en)	2015-02-20	2016-08-25	Incyte Corporation	Bicyclic heterocycles as fgfr4 inhibitors
MA41551A (fr)	2015-02-20	2017-12-26	Incyte Corp	Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
MX2017010673A (es)	2015-02-20	2018-03-21	Incyte Corp	Heterociclos biciclicos como inhibidores de receptores del factor de crecimiento fibroblastico (fgfr).
US10111885B2 (en)	2015-03-13	2018-10-30	Resverlogix Corp.	Compositions and therapeutic methods for the treatment of complement-associated diseases
TWI703984B (zh) *	2015-04-03	2020-09-11	英商阿斯特克斯治療有限公司	用於癌症治療之fgfr/pd-1組合療法
US10478494B2 (en) *	2015-04-03	2019-11-19	Astex Therapeutics Ltd	FGFR/PD-1 combination therapy for the treatment of cancer
HUE057090T2 (hu) *	2015-09-23	2022-04-28	Janssen Pharmaceutica Nv	BI-heteroaril-szubsztituált 1,4-benzodiazepinek és alkalmazásuk rák kezelésében
US11155555B2 (en) *	2015-09-23	2021-10-26	Janssen Pharmaceutica Nv	Compounds
CN105596330B (zh) *	2015-12-11	2018-10-16	深圳市坤健创新药物研究院	虚拟筛选化合物在制备激酶抑制剂中的应用和药物
CN107459519A (zh)	2016-06-06	2017-12-12	上海艾力斯医药科技有限公司	稠合嘧啶哌啶环衍生物及其制备方法和应用
WO2018049233A1 (en)	2016-09-08	2018-03-15	Nicolas Stransky	Inhibitors of the fibroblast growth factor receptor in combination with cyclin-dependent kinase inhibitors
RU2019113764A (ru) *	2016-10-10	2020-11-13	Девелопмент Сентер Фор Байотекнолоджи	Соединения хиноксалина в качестве ингибиторов рецепторной тирозинкиназы iii типа
AR111960A1 (es)	2017-05-26	2019-09-04	Incyte Corp	Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
JOP20190280A1 (ar)	2017-06-02	2019-12-02	Janssen Pharmaceutica Nv	مثبطات fgfr2 لعلاج سرطان الأوعية الصفراوية
WO2019040109A1 (en) *	2017-08-21	2019-02-28	Celgene Corporation	PROCESSES FOR THE PREPARATION OF (S) -TERT-BUTYL 4,5-DIAMINO-5-OXOPENTANOATE
US11661411B2 (en)	2017-12-01	2023-05-30	Board Of Regents Of The University Of Nebraska	Quinoxaline compounds and uses thereof
MX2020008610A (es)	2018-03-28	2020-09-21	Eisai R&D Man Co Ltd	Agente terapeutico para carcinoma hepatocelular.
WO2019209083A1 (ko) *	2018-04-26	2019-10-31	재단법인 의약바이오컨버젼스연구단	mTOR 저해제로서의 신규 화합물 및 이의 용도
CN112566912A (zh)	2018-05-04	2021-03-26	因赛特公司	Fgfr抑制剂的盐
CN112867716A (zh)	2018-05-04	2021-05-28	因赛特公司	Fgfr抑制剂的固体形式和其制备方法
AU2019342289A1 (en)	2018-09-21	2021-03-18	Janssen Pharmaceutica Nv	Treatment of cholangiocarcinoma
EP3898615A1 (en) *	2018-12-19	2021-10-27	Array Biopharma, Inc.	7-((3,5-dimethoxyphenyl)amino)quinoxaline derivatives as fgfr inhibitors for treating cancer
WO2020185532A1 (en)	2019-03-08	2020-09-17	Incyte Corporation	Methods of treating cancer with an fgfr inhibitor
KR20210145211A (ko)	2019-03-29	2021-12-01	얀센 파마슈티카 엔.브이.	요로상피세포암종의 치료를 위한 fgfr 티로신 키나제 저해제
CN113645975A (zh)	2019-03-29	2021-11-12	詹森药业有限公司	用于治疗尿路上皮癌的fgfr酪氨酸激酶抑制剂
WO2020208592A1 (en) *	2019-04-12	2020-10-15	Dr. Reddy’S Laboratories Limited	Process for preparation of erdafitinib, its purification and amorphous solid dispersion
CN111909044A (zh) *	2019-05-09	2020-11-10	南京爱德程医药科技有限公司	2-(烷基氨基)乙基苯甲酸酯类化合物的合成方法
WO2021007269A1 (en)	2019-07-09	2021-01-14	Incyte Corporation	Bicyclic heterocycles as fgfr inhibitors
TWI759829B (zh) *	2019-08-23	2022-04-01	財團法人生物技術開發中心	作為第iii型受體酪胺酸激酶抑制劑之雜環吡唑衍生物
US20220348662A1 (en)	2019-09-26	2022-11-03	Janssen Pharmaceutica Nv	Use of fgfr inhibitors in fgfr-genetically altered cancers to enhance patient response to immune checkpoint inhibitors in sequential treatment settings
AU2020366006A1 (en)	2019-10-14	2022-04-21	Incyte Corporation	Bicyclic heterocycles as FGFR inhibitors
US11566028B2 (en)	2019-10-16	2023-01-31	Incyte Corporation	Bicyclic heterocycles as FGFR inhibitors
CN110790677B (zh) *	2019-11-05	2022-04-29	浙江工业大学	一种金刚烷甲酰胺类化合物及其制备方法和应用
EP4069696A1 (en)	2019-12-04	2022-10-12	Incyte Corporation	Tricyclic heterocycles as fgfr inhibitors
KR20220131900A (ko)	2019-12-04	2022-09-29	인사이트 코포레이션	Fgfr 억제제의 유도체
CN113024517A (zh) *	2019-12-09	2021-06-25	武汉九州钰民医药科技有限公司	一种制备厄达替尼的方法
CN113024518A (zh) *	2019-12-09	2021-06-25	武汉九州钰民医药科技有限公司	一种厄达替尼的制备方法
CN114945367A (zh) *	2020-01-17	2022-08-26	贝达医药公司	作为fgfr激酶抑制剂的哒嗪和1,2,4-三嗪衍生物
TW202140012A (zh)	2020-02-12	2021-11-01	比利時商健生藥品公司	用於治療尿路上皮癌的ｆｇｆｒ酪胺酸激酶抑制劑和抗ｐｄ１藥劑
KR20220140781A (ko)	2020-02-12	2022-10-18	얀센 파마슈티카 엔.브이.	고위험 비근침윤성 방광암 치료를 위한 fgfr 티로신 키나제 억제제
WO2022040111A2 (en)	2020-08-17	2022-02-24	Teva Pharmaceuticals International Gmbh	Solid state forms of erdafitinib salts and processes for preparation of erdafitinib
CN112920167B (zh) *	2020-08-19	2022-08-26	四川大学华西医院	靶向fgfr和hdac的双靶点抑制剂及其制备方法和应用、药物组合物及药剂
EP4210702A1 (en)	2020-09-14	2023-07-19	JANSSEN Pharmaceutica NV	Fgfr inhibitor combination therapies
CA3217517A1 (en)	2021-05-19	2022-11-24	Christopher H. Moy	Fgfr tyrosine kinase inhibitors for the treatment of advanced solid tumors
US11939331B2 (en)	2021-06-09	2024-03-26	Incyte Corporation	Tricyclic heterocycles as FGFR inhibitors
CN117858872A (zh)	2021-06-22	2024-04-09	缆图药品公司	用于治疗癌症的杂环egfr抑制剂
TW202333720A (zh)	2021-10-12	2023-09-01	美商塔里斯生物醫學有限責任公司	用於膀胱內施用的厄達替尼調配物及系統
WO2023081923A1 (en)	2021-11-08	2023-05-11	Frequency Therapeutics, Inc.	Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof
TW202400174A (zh) *	2022-02-18	2024-01-01	美商塔里斯生物醫學有限責任公司	用於膀胱內施用的Erdafitinib調配物及滲透系統
CN115108926B (zh) *	2022-04-02	2023-06-20	上海工程技术大学	一种用于制备厄达替尼的中间体化合物及制备方法

Family Cites Families (128)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2940972A (en)	1957-06-27	1960-06-14	Thomae Gmbh Dr K	Tri-and tetra-substituted pteridine derivatives
US4666828A (en)	1984-08-15	1987-05-19	The General Hospital Corporation	Test for Huntington's disease
US4683202A (en)	1985-03-28	1987-07-28	Cetus Corporation	Process for amplifying nucleic acid sequences
US4801531A (en)	1985-04-17	1989-01-31	Biotechnology Research Partners, Ltd.	Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5272057A (en)	1988-10-14	1993-12-21	Georgetown University	Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en)	1989-08-25	1993-03-09	Genetype Ag	Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
GB9125001D0 (en)	1991-11-25	1992-01-22	Ici Plc	Heterocyclic compounds
AU6909194A (en)	1993-05-14	1994-12-12	Board Of Regents, The University Of Texas System	Preparation of n-cyanodithioimino-carbonates and 3-mercapto-5-amino-1h-1,2,4-triazole
US5700823A (en)	1994-01-07	1997-12-23	Sugen, Inc.	Treatment of platelet derived growth factor related disorders such as cancers
US6331555B1 (en)	1995-06-01	2001-12-18	University Of California	Treatment of platelet derived growth factor related disorders such as cancers
CA2262403C (en)	1995-07-31	2011-09-20	Urocor, Inc.	Biomarkers and targets for diagnosis, prognosis and management of prostate disease
US6218529B1 (en)	1995-07-31	2001-04-17	Urocor, Inc.	Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer
TW472045B (en)	1996-09-25	2002-01-11	Astra Ab	Protein kinase C inhibitor compounds, method for their preparation, pharmaceutical composition thereof and intermediate used for their preparation
EP0991628B1 (en)	1997-05-28	2005-01-12	Aventis Pharmaceuticals Inc	QUINOLINE AND QUINOXALINE COMPOUNDS WHICH INHIBIT PLATELET-DERIVED GROWTH FACTOR AND/OR P56lck TYROSINE KINASES
US6235740B1 (en)	1997-08-25	2001-05-22	Bristol-Myers Squibb Co.	Imidazoquinoxaline protein tyrosine kinase inhibitors
UA71555C2 (en)	1997-10-06	2004-12-15	Zentaris Gmbh	Methods for modulating function of serine/threonine protein kinases by 5-azaquinoline derivatives
WO2000042026A1 (en)	1999-01-15	2000-07-20	Novo Nordisk A/S	Non-peptide glp-1 agonists
OA12010A (en)	1999-09-15	2006-04-19	Warner Lambert Co	Pteridinones as kinase inhibitors.
DE10013318A1 (de)	2000-03-17	2001-09-20	Merck Patent Gmbh	Formulierung enthaltend Chinoxalinderivate
WO2002076985A1 (en)	2001-03-23	2002-10-03	Smithkline Beecham Corporation	Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
EP1458383B1 (en)	2001-12-18	2007-11-21	Merck & Co., Inc.	Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5
PT1463506E (pt)	2001-12-24	2009-12-10	Astrazeneca Ab	Derivados de quinazolina substituídos como inibidores de aurora cinases
JP2003213463A (ja)	2002-01-17	2003-07-30	Sumitomo Chem Co Ltd	金属腐食防止剤および洗浄液
JP4394960B2 (ja)	2002-04-08	2010-01-06	メルクエンドカムパニーインコーポレーテッド	Ａｋｔ活性阻害薬
US6962995B2 (en)	2002-07-10	2005-11-08	E. I. Du Pont De Nemours And Company	Charge transport compositions and electronic devices made with such compositions
US7825132B2 (en)	2002-08-23	2010-11-02	Novartis Vaccines And Diagnostics, Inc.	Inhibition of FGFR3 and treatment of multiple myeloma
KR20110050745A (ko)	2002-10-03	2011-05-16	탈자진 인코포레이티드	혈관항상성 유지제 및 그의 사용 방법
AR043059A1 (es)	2002-11-12	2005-07-13	Bayer Pharmaceuticals Corp	Derivados de indolil pirazinona utiles para el tratamiento de trastornos hiper-proliferativos
US7098332B2 (en)	2002-12-20	2006-08-29	Hoffmann-La Roche Inc.	5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones
BRPI0406809A (pt)	2003-01-17	2005-12-27	Warner Lambert Co	Heterociclos substituìdos de 2-aminopiridina como inibidores da proliferação celular
EP1620413A2 (en)	2003-04-30	2006-02-01	Cytokinetics, Inc.	Compounds, compositions, and methods
JP4847868B2 (ja)	2003-05-14	2011-12-28	ニューロジェネティックファーマシューティカルズ、インコーポレイテッド	化合物、及び、アミロイドベータの調節におけるその使用
DE10323345A1 (de)	2003-05-23	2004-12-16	Zentaris Gmbh	Neue Pyridopyrazine und deren Verwendung als Kinase-Inhibitoren
NZ544112A (en)	2003-05-23	2010-01-29	Zentaris Gmbh	Novel pyridopyrazines and use thereof as kinase modulators
WO2005007099A2 (en)	2003-07-10	2005-01-27	Imclone Systems Incorporated	Pkb inhibitors as anti-tumor agents
WO2005009437A1 (en)	2003-07-21	2005-02-03	Bethesda Pharmaceuticals, Inc.	Design and synthesis of optimized ligands for ppar
JP2007501189A (ja)	2003-08-01	2007-01-25	ジェネラブステクノロジーズ，インコーポレイテッド	フラビウイルス科に対する二環式イミダゾール誘導体
DK1673092T3 (da)	2003-10-17	2007-12-17	4 Aza Ip Nv	Heterocyklylsubstituerede pteridinderivater og anvendelsen deraf i terapi
JP4823914B2 (ja)	2003-11-07	2011-11-24	ノバルティスバクシンズアンドダイアグノスティックス，インコーポレーテッド	Ｆｇｆｒ３の阻害および多発性骨髄腫の治療
EP1687277B1 (en)	2003-11-20	2018-04-04	Janssen Pharmaceutica NV	6-alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(adp-ribose) polymerase inhibitors
JP2007512275A (ja)	2003-11-24	2007-05-17	エフ．ホフマン−ラ　ロシュ　アーゲー	ピラゾリルおよびイミダゾリルピリミジン
EP1706385B1 (en) *	2003-12-23	2010-10-06	Astex Therapeutics Limited	Pyrazole derivatives as protein kinase modulators
US7098222B2 (en)	2004-05-12	2006-08-29	Abbott Laboratories	Bicyclic-substituted amines having cyclic-substituted monocyclic substituents
US7205316B2 (en)	2004-05-12	2007-04-17	Abbott Laboratories	Tri- and bi-cyclic heteroaryl histamine-3 receptor ligands
NZ553087A (en)	2004-08-31	2010-12-24	Astrazeneca Ab	Quinazolinone derivatives and their use as B-raf inhibitors
CN101039944B (zh)	2004-10-14	2010-05-05	霍夫曼-拉罗奇有限公司	具有cdk1抗增殖活性的1,5-二氮杂萘唑烷酮类
US20080207616A1 (en)	2004-10-15	2008-08-28	Astrazeneca Ab	Quinoxalines as B Baf Inhhibitors
JP4966202B2 (ja)	2004-12-24	2012-07-04	スピニフェクスファーマシューティカルズピーティーワイリミテッド	治療または予防のための方法
NZ556686A (en)	2005-02-14	2010-01-29	Bionomics Ltd	Novel tubulin polymerisation inhibitors
US9271963B2 (en)	2005-03-03	2016-03-01	Universitat Des Saarlandes	Selective inhibitors of human corticosteroid synthases
EP1881986A2 (en)	2005-05-12	2008-01-30	Merck & Co., Inc.	Tyrosine kinase inhibitors
AU2006247315A1 (en)	2005-05-18	2006-11-23	Wyeth	4, 6-diamino-[1,7] naphthyridine-3-carbonitrile inhibitors of Tpl2 kinase and methods of making and using the same
GB0513692D0 (en)	2005-07-04	2005-08-10	Karobio Ab	Novel pharmaceutical compositions
WO2007023186A1 (en)	2005-08-26	2007-03-01	Laboratoires Serono S.A.	Pyrazine derivatives and use as pi3k inhibitors
EP1957487A1 (de)	2005-11-11	2008-08-20	AEterna Zentaris GmbH	Neue pyridopyrazine und deren verwendung als modulatoren von kinasen
EP1790342A1 (de)	2005-11-11	2007-05-30	Zentaris GmbH	Pyridopyrazin-Derivate und deren Verwendung als Modulatoren der Signaltransduktionswege
US8217042B2 (en)	2005-11-11	2012-07-10	Zentaris Gmbh	Pyridopyrazines and their use as modulators of kinases
ME02736B (me)	2005-12-21	2017-10-20	Janssen Pharmaceutica Nv	Triazolopiridazini kao modulatori tirozin kinaze
US7998978B2 (en)	2006-05-01	2011-08-16	Pfizer Inc.	Substituted 2-amino-fused heterocyclic compounds
GB0609621D0 (en)	2006-05-16	2006-06-21	Astrazeneca Ab	Novel co-crystal
JP2009537590A (ja)	2006-05-24	2009-10-29	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	四員複素環で置換された置換プテリジン
TWI398252B (zh)	2006-05-26	2013-06-11	Novartis Ag	吡咯并嘧啶化合物及其用途
AU2007271187A1 (en)	2006-07-03	2008-01-10	Vereniging Voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek En Patientenzorg	Fused bicyclic compounds interacting with the histamine H4 receptor
EP2081928B1 (en)	2006-11-10	2014-02-26	Bristol-Myers Squibb Company	Pyrrolo-pyridine kinase inhibitors
JP2008127446A (ja)	2006-11-20	2008-06-05	Canon Inc	１，５−ナフチリジン化合物及び有機発光素子
CN102123712B (zh)	2006-12-13	2014-03-19	默沙东公司	使用igf1r抑制剂治疗癌症的方法
MX2009006688A (es)	2006-12-21	2009-06-30	Plexxikon Inc	Compuestos y metodos para modulacion de cinasas, e indicaciones para ello.
JP2010514693A (ja)	2006-12-22	2010-05-06	ノバルティスアーゲー	Ｐｄｋ１阻害のためのキナゾリン
MX2009006706A (es) *	2006-12-22	2009-07-02	Astex Therapeutics Ltd	Compuestos heterociclicos biciclicos como inhibidores del receptor del factor de crecimiento de fibroblastos.
KR20080062876A (ko)	2006-12-29	2008-07-03	주식회사 대웅제약	신규한 항진균성 트리아졸 유도체
EP1990342A1 (en)	2007-05-10	2008-11-12	AEterna Zentaris GmbH	Pyridopyrazine Derivatives, Process of Manufacturing and Uses thereof
US7592342B2 (en) *	2007-05-10	2009-09-22	Smithkline Beecham Corporation	Quinoxaline derivatives as PI3 kinase inhibitors
JP2010529031A (ja)	2007-05-29	2010-08-26	グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー	Ｐｉ３キナーゼ阻害剤としてのナフチリジン誘導体
AR066879A1 (es)	2007-06-08	2009-09-16	Novartis Ag	Derivados de quinoxalina como inhibidores de la actividad de cinasa de tirosina de las cinasas janus
PT2172450E (pt)	2007-06-20	2013-10-28	Mitsubishi Tanabe Pharma Corp	Novo derivado sulfonamida de ácido malónico e sua utilização farmacêutica
JP5548123B2 (ja)	2007-06-21	2014-07-16	ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ	６−｛ジフルオロ［６−（１−メチル−１Ｈ−ピラゾル−４−イル）［１，２，４］トリアゾロ［４，３−ｂ］ピリダジン−３−イル］メチル｝キノリンの多形および水和物の形態、塩、ならびに製造方法
WO2009009016A1 (en)	2007-07-06	2009-01-15	Osi Pharmaceuticals, Inc.	Combination anti-cancer therapy
CN101827848B (zh)	2007-08-08	2012-11-07	葛兰素史密丝克莱恩有限责任公司	作为IGF-1R抑制剂用于治疗癌症的2-[(2-{苯基氨基}-1H-吡咯并[2,3-d]嘧啶-4-基)氨基]苯甲酰胺衍生物
WO2009019518A1 (en)	2007-08-09	2009-02-12	Astrazeneca Ab	Pyrimidine compounds having a fgfr inhibitory effect
EP2173354A4 (en) *	2007-08-09	2011-10-05	Glaxosmithkline Llc	CHINOXALIN DERIVATIVES AS PI3 KINASE INHIBITORS
US20090054304A1 (en)	2007-08-23	2009-02-26	Kalypsys, Inc.	Heterocyclic modulators of tgr5 for treatment of disease
CA2704599C (en)	2007-11-16	2015-05-12	Incyte Corporation	4-pyrazolyl-n-arylpyrimidin-2-amines and 4-pyrazolyl-n-heteroarylpyrimidin-2-amines as janus kinase inhibitors
CA2722992A1 (en)	2008-05-05	2009-11-12	Schering Corporation	Sequential administration of chemotherapeutic agents for treatment of cancer
CA2725185C (en)	2008-05-23	2016-10-25	Novartis Ag	Derivatives of quinolines and quinoxalines as protein tyrosine kinase inhibitors
JP2012509342A (ja)	2008-11-20	2012-04-19	オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド	置換ピロロ［２，３−ｂ］−ピリジンおよび−ピラジン
EP2389376A1 (en)	2009-01-21	2011-11-30	Basilea Pharmaceutica AG	Novel bicyclic antibiotics
AU2010208480A1 (en)	2009-02-02	2011-07-28	Msd K.K.	Inhibitors of Akt activity
TW201041888A (en)	2009-05-06	2010-12-01	Plexxikon Inc	Compounds and methods for kinase modulation, and indications therefor
CN104945379B (zh)	2009-06-12	2018-11-30	Abivax公司	用于治疗过早衰老和尤其是早衰的化合物
EA021275B9 (ru)	2009-09-03	2015-08-31	Байоэнердженикс	Гетероциклические соединения, содержащая их фармацевтическая композиция и их применение для лечения pask-опосредованного заболевания
EP2473498A1 (en)	2009-09-04	2012-07-11	Bayer Pharma Aktiengesellschaft	Substituted aminoquinoxalines as tyrosine threonine kinase inhibitors
US20110123545A1 (en)	2009-11-24	2011-05-26	Bristol-Myers Squibb Company	Combination of vegfr2 and igf1r inhibitors for the treatment of proliferative diseases
EP2332939A1 (en)	2009-11-26	2011-06-15	Æterna Zentaris GmbH	Novel Naphthyridine derivatives and the use thereof as kinase inhibitors
CN104940200B (zh)	2010-03-30	2019-06-28	维颂公司	多取代芳族化合物作为凝血酶的抑制剂
GB201007286D0 (en)	2010-04-30	2010-06-16	Astex Therapeutics Ltd	New compounds
WO2011146591A1 (en)	2010-05-19	2011-11-24	Millennium Pharmaceuticals, Inc.	Substituted hydroxamic acids and uses thereof
CA2804304C (en)	2010-05-24	2020-02-25	Intellikine, Llc	Heterocyclic compounds and uses thereof
GB201020179D0 (en)	2010-11-29	2011-01-12	Astex Therapeutics Ltd	New compounds
CN102532141A (zh)	2010-12-08	2012-07-04	中国科学院上海药物研究所	[1，2，4]***并[4，3-b][1，2，4]三嗪类化合物、其制备方法和用途
CA2825605C (en)	2011-01-31	2019-05-07	Novartis Ag	Heterocyclic derivatives
AU2012212075A1 (en)	2011-02-02	2013-07-18	Amgen Inc.	Methods and compositons relating to inhibition of IGF-1R
AR085397A1 (es)	2011-02-23	2013-09-25	Intellikine Inc	Combinacion de inhibidores de quinasa y sus usos
WO2012118492A1 (en)	2011-03-01	2012-09-07	Array Biopharma Inc.	Heterocyclic sulfonamides as raf inhibitors
US9896730B2 (en)	2011-04-25	2018-02-20	OSI Pharmaceuticals, LLC	Use of EMT gene signatures in cancer drug discovery, diagnostics, and treatment
CN107245056A (zh)	2011-08-26	2017-10-13	润新生物公司	化学实体、组合物及方法
WO2013040515A1 (en)	2011-09-14	2013-03-21	Neupharma, Inc.	Certain chemical entities, compositions, and methods
WO2013043935A1 (en)	2011-09-21	2013-03-28	Neupharma, Inc.	Certain chemical entites, compositions, and methods
WO2013052699A2 (en)	2011-10-04	2013-04-11	Gilead Calistoga Llc	Novel quinoxaline inhibitors of pi3k
PL2771342T3 (pl)	2011-10-28	2016-11-30		Nowe pochodne puryny i ich zastosowanie w leczeniu chorób
GB201118654D0 (en)	2011-10-28	2011-12-07	Astex Therapeutics Ltd	New compounds
JO3210B1 (ar)	2011-10-28	2018-03-08	Merck Sharp & Dohme	مثبط منصهر لبروتين نقل الكوليسترليستير اوكسازوليدينون ثمائي الحلقة
GB201118652D0 (en)	2011-10-28	2011-12-07	Astex Therapeutics Ltd	New compounds
GB201118675D0 (en)	2011-10-28	2011-12-14	Astex Therapeutics Ltd	New compounds
GB201118656D0 (en)	2011-10-28	2011-12-07	Astex Therapeutics Ltd	New compounds
US9481911B2 (en)	2012-03-08	2016-11-01	Astellas Pharma Inc.	Methods for detecting FGFR3/TACC3 fusion genes
GB201209613D0 (en)	2012-05-30	2012-07-11	Astex Therapeutics Ltd	New compounds
GB201209609D0 (en) *	2012-05-30	2012-07-11	Astex Therapeutics Ltd	New compounds
US20150203589A1 (en)	2012-07-24	2015-07-23	The Trustees Of Columbia University In The City Of New York	Fusion proteins and methods thereof
WO2014113729A2 (en)	2013-01-18	2014-07-24	Foundation Mecicine, Inc.	Methods of treating cholangiocarcinoma
GB201307577D0 (en)	2013-04-26	2013-06-12	Astex Therapeutics Ltd	New compounds
JP2016527274A (ja)	2013-08-02	2016-09-08	イグナイタインコーポレイテッド	ＡＸＬ／ｃＭＥＴ阻害剤を単独または他の薬剤と組み合わせて用いて各種がんを治療する方法
US9221804B2 (en)	2013-10-15	2015-12-29	Janssen Pharmaceutica Nv	Secondary alcohol quinolinyl modulators of RORγt
JO3512B1 (ar)	2014-03-26	2020-07-05	Astex Therapeutics Ltd	مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
ES2856482T3 (es)	2014-03-26	2021-09-27	Astex Therapeutics Ltd	Combinaciones de inhibidores de FGFR y cMet para el tratamiento del cáncer
HUE053653T2 (hu)	2014-03-26	2021-07-28	Astex Therapeutics Ltd	FGFR inhibitor és IGF1R inhibitor kombinációi
JOP20200201A1 (ar)	2015-02-10	2017-06-16	Astex Therapeutics Ltd	تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين
MX2017010595A (es)	2015-02-19	2018-11-12	Bioclin Therapeutics Inc	Métodos, composiciones, y equipos para tratamiento de cáncer.
US10478494B2 (en)	2015-04-03	2019-11-19	Astex Therapeutics Ltd	FGFR/PD-1 combination therapy for the treatment of cancer

2010
- 2010-04-30 GB GB201007286A patent/GB201007286D0/en not_active Ceased
2011
- 2011-04-19 JO JOP/2011/0133A patent/JO3366B1/ar active
- 2011-04-27 TW TW100114665A patent/TWI545122B/zh active
- 2011-04-28 HU HUE11724710A patent/HUE033702T2/en unknown
- 2011-04-28 PL PL11724710T patent/PL2563775T3/pl unknown
- 2011-04-28 HR HRP20211675TT patent/HRP20211675T1/hr unknown
- 2011-04-28 PL PL19175481T patent/PL3590934T3/pl unknown
- 2011-04-28 PL PL16207610T patent/PL3178818T3/pl unknown
- 2011-04-28 WO PCT/GB2011/050851 patent/WO2011135376A1/en active Application Filing
- 2011-04-28 DK DK11724710.6T patent/DK2563775T3/en active
- 2011-04-28 CR CR20180339A patent/CR20180339A/es unknown
- 2011-04-28 HU HUE19175481A patent/HUE056999T2/hu unknown
- 2011-04-28 AU AU2011247047A patent/AU2011247047B2/en active Active
- 2011-04-28 DK DK19175481.1T patent/DK3590934T3/da active
- 2011-04-28 EA EA201500278A patent/EA028599B1/ru unknown
- 2011-04-28 RS RS20170353A patent/RS55863B1/sr unknown
- 2011-04-28 SG SG10201708578QA patent/SG10201708578QA/en unknown
- 2011-04-28 MY MYPI2016001863A patent/MY191669A/en unknown
- 2011-04-28 MX MX2015012476A patent/MX365702B/es unknown
- 2011-04-28 MX MX2012012414A patent/MX2012012414A/es active IP Right Grant
- 2011-04-28 SI SI201131112A patent/SI2563775T1/sl unknown
- 2011-04-28 CN CN201180021785.5A patent/CN102858765B/zh active Active
- 2011-04-28 AP AP2012006490A patent/AP3210A/xx active
- 2011-04-28 EA EA201291143A patent/EA023222B8/ru unknown
- 2011-04-28 ES ES19175481T patent/ES2899937T3/es active Active
- 2011-04-28 HU HUE16207610A patent/HUE045893T2/hu unknown
- 2011-04-28 PT PT191754811T patent/PT3590934T/pt unknown
- 2011-04-28 EP EP16207610.3A patent/EP3178818B1/en active Active
- 2011-04-28 SI SI201132013T patent/SI3590934T1/sl unknown
- 2011-04-28 LT LTEP16207610.3T patent/LT3178818T/lt unknown
- 2011-04-28 SG SG2012078085A patent/SG184966A1/en unknown
- 2011-04-28 LT LTEP19175481.1T patent/LT3590934T/lt unknown
- 2011-04-28 RS RSP20191045 patent/RS59196B1/sr unknown
- 2011-04-28 AR ARP110101476 patent/AR080982A1/es active IP Right Grant
- 2011-04-28 NZ NZ602726A patent/NZ602726A/en unknown
- 2011-04-28 EP EP19175481.1A patent/EP3590934B1/en active Active
- 2011-04-28 LT LTEP11724710.6T patent/LT2563775T/lt unknown
- 2011-04-28 US US13/643,741 patent/US8895601B2/en active Active
- 2011-04-28 ES ES16207610T patent/ES2742409T3/es active Active
- 2011-04-28 PT PT16207610T patent/PT3178818T/pt unknown
- 2011-04-28 ES ES11724710.6T patent/ES2621461T3/es active Active
- 2011-04-28 KR KR1020127031310A patent/KR101889565B1/ko active Protection Beyond IP Right Term
- 2011-04-28 DK DK16207610.3T patent/DK3178818T3/da active
- 2011-04-28 ME MEP-2013-123A patent/ME01825B/me unknown
- 2011-04-28 PT PT117247106T patent/PT2563775T/pt unknown
- 2011-04-28 IN IN2591MUN2012 patent/IN2012MN02591A/en unknown
- 2011-04-28 CA CA2796204A patent/CA2796204C/en active Active
- 2011-04-28 RS RS20211397A patent/RS62570B1/sr unknown
- 2011-04-28 KR KR1020187023217A patent/KR101933843B1/ko active IP Right Grant
- 2011-04-28 EP EP11724710.6A patent/EP2563775B1/en active Active
- 2011-04-28 MY MYPI2012004699A patent/MY189427A/en unknown
- 2011-04-28 SI SI201131755T patent/SI3178818T1/sl unknown
- 2011-04-28 CN CN201510087109.8A patent/CN104725362B/zh active Active
- 2011-04-28 JP JP2013506755A patent/JP5639261B2/ja active Active
- 2011-04-28 BR BR112012027509-7A patent/BR112012027509B1/pt active IP Right Grant
2012
- 2012-10-22 IL IL222600A patent/IL222600A/en active IP Right Grant
- 2012-10-30 CL CL2012003048A patent/CL2012003048A1/es unknown
- 2012-11-13 CR CR20120576A patent/CR20120576A/es unknown
- 2012-11-29 EC ECSP12012318 patent/ECSP12012318A/es unknown
2014
- 2014-10-02 US US14/505,020 patent/US9464071B2/en active Active
2016
- 2016-04-28 US US15/141,061 patent/US9850228B2/en active Active
2017
- 2017-04-18 AU AU2017202512A patent/AU2017202512B2/en active Active
- 2017-11-13 US US15/810,521 patent/US10519137B2/en active Active
2019
- 2019-08-09 CY CY20191100858T patent/CY1121882T1/el unknown
- 2019-10-25 US US16/663,579 patent/US20200131153A1/en not_active Abandoned
2021
- 2021-10-20 US US17/451,601 patent/US20220135544A1/en active Pending
- 2021-11-23 CY CY20211101014T patent/CY1124928T1/el unknown

Also Published As

Publication number	Publication date
US9850228B2 (en)	2017-12-26
CR20180339A (es)	2018-11-12
EP3178818A1 (en)	2017-06-14
GB201007286D0 (en)	2010-06-16
KR101933843B1 (ko)	2018-12-28
EA023222B1 (ru)	2016-05-31
HUE056999T2 (hu)	2022-04-28
HRP20211675T1 (hr)	2022-02-18
SI3590934T1 (sl)	2022-03-31
AP2012006490A0 (en)	2012-10-31
US20150105368A1 (en)	2015-04-16
EA028599B1 (ru)	2017-12-29
ES2742409T3 (es)	2020-02-14
LT2563775T (lt)	2017-04-10
CA2796204A1 (en)	2011-11-03
AU2017202512B2 (en)	2018-07-26
TW201204714A (en)	2012-02-01
CY1121882T1 (el)	2020-10-14
PL3590934T3 (pl)	2022-02-07
MY191669A (en)	2022-07-06
HUE033702T2 (en)	2017-12-28
BR112012027509A2 (pt)	2017-08-08
PT3590934T (pt)	2021-11-25
RS62570B1 (sr)	2021-12-31
SG184966A1 (en)	2012-11-29
SG10201708578QA (en)	2017-11-29
WO2011135376A1 (en)	2011-11-03
CN102858765B (zh)	2015-04-01
CN102858765A (zh)	2013-01-02
BR112012027509B1 (pt)	2022-07-05
CA2796204C (en)	2020-08-25
PT2563775T (pt)	2017-04-18
US20200131153A1 (en)	2020-04-30
AP3210A (en)	2015-04-30
US8895601B2 (en)	2014-11-25
RS59196B1 (sr)	2019-10-31
AR080982A1 (es)	2012-05-23
US20160311800A1 (en)	2016-10-27
CL2012003048A1 (es)	2013-04-19
ES2621461T3 (es)	2017-07-04
CN104725362A (zh)	2015-06-24
IL222600A (en)	2016-02-29
EP3590934A1 (en)	2020-01-08
EA201291143A1 (ru)	2013-05-30
IL222600A0 (en)	2012-12-31
HUE045893T2 (hu)	2020-01-28
PL2563775T3 (pl)	2017-07-31
IN2012MN02591A (es)	2015-06-12
JP2013528580A (ja)	2013-07-11
SI2563775T1 (sl)	2017-05-31
AU2011247047B2 (en)	2017-01-19
EP2563775B1 (en)	2017-01-04
KR20180093134A (ko)	2018-08-20
US20180127397A1 (en)	2018-05-10
EP3590934B1 (en)	2021-08-25
MY189427A (en)	2022-02-11
LT3178818T (lt)	2019-08-12
PT3178818T (pt)	2019-09-05
AU2011247047A1 (en)	2013-01-10
KR20130108076A (ko)	2013-10-02
DK3590934T3 (da)	2021-11-08
SI3178818T1 (sl)	2019-09-30
DK2563775T3 (en)	2017-03-27
MX365702B (es)	2019-06-11
TWI545122B (zh)	2016-08-11
KR101889565B1 (ko)	2018-08-17
US9464071B2 (en)	2016-10-11
EP2563775A1 (en)	2013-03-06
RS55863B1 (sr)	2017-08-31
BR112012027509A8 (pt)	2021-11-03
US20220135544A1 (en)	2022-05-05
NZ602726A (en)	2014-05-30
JO3366B1 (ar)	2019-03-13
PL3178818T3 (pl)	2019-11-29
ME01825B (me)	2014-12-20
EP3178818B1 (en)	2019-05-22
CY1124928T1 (el)	2023-01-05
LT3590934T (lt)	2021-12-27
CN104725362B (zh)	2017-04-12
EA023222B8 (ru)	2017-04-28
DK3178818T3 (da)	2019-07-22
US10519137B2 (en)	2019-12-31
AU2017202512A1 (en)	2017-05-04
ECSP12012318A (es)	2013-02-28
MX2012012414A (es)	2013-02-26
US20130072457A1 (en)	2013-03-21
EA201500278A1 (ru)	2015-09-30
ES2899937T3 (es)	2022-03-15
JP5639261B2 (ja)	2014-12-10

Publication	Publication Date	Title
SMT201500271B (it)	2016-01-08	Inibitori di neprilisina
CR20120576A (es)	2013-03-04	Inhibidores de pirazolil quinazolina cinasa
BR112012028556A2 (pt)	2014-04-01	Indóis
DE102011100241A8 (de)	2012-03-01	Nitridhalbleiterbauteil
DK3225404T3 (da)	2020-02-10	Fluidpatron
CR20130111A (es)	2013-05-29	Triazina-oxidiazoles
DE10170954T8 (de)	2013-04-25	Mikrowellendruckgarer
BR112013016154A2 (pt)	2018-07-10	inibidores de faah
DE112011104226A5 (de)	2013-09-26	Käfigmutter
DE102011117046A8 (de)	2012-12-27	Doppelkupplungswindungsgetriebe
DE112011101226A5 (de)	2013-01-24	Linearwegmesssystem
DE112011102080A5 (de)	2013-04-11	Kupplungszentralausrücker
DK2442899T3 (da)	2013-10-07	Rotorskive
DK2539163T3 (da)	2015-09-21	Dækventil
DE102011002623A8 (de)	2012-02-02	Ventilsteuerzeitversteller
DE112011102711A5 (de)	2013-05-29	Hydrostataktor
DK2448659T3 (da)	2013-07-22	Rotorskive
DK2447426T3 (da)	2013-06-03	Vaske-WC
DE102010019119B8 (de)	2013-01-31	Cuttermesser
BR112013014148A2 (pt)	2016-09-27	inibidores de corrosão
DE112010005518A5 (de)	2013-04-25	Dichtungsmanchette
DE102010038420A8 (de)	2013-01-10	Reinigungungsvorrichtung
DK2596072T3 (da)	2014-08-11	Bor-forbindelses-suspension
DK2521486T3 (da)	2020-02-03	Palpometer
CO6801789A2 (es)	2013-11-29	N-hetarilmetil pirazolilcarboxamidas